BetterLife Pharma (OTCMKTS:BETRF – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, Zacks reports.
BetterLife Pharma Trading Down 6.5%
BetterLife Pharma stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.21. 104,635 shares of the company traded hands, compared to its average volume of 90,412. The firm’s fifty day moving average is $0.22 and its two-hundred day moving average is $0.12. BetterLife Pharma has a fifty-two week low of $0.03 and a fifty-two week high of $0.33.
About BetterLife Pharma
BetterLife Pharma Inc is a Canadian biotechnology company focused on developing novel treatments for mental health and neurological conditions. Its research programs are centered on pharmaceutical compounds derived from or inspired by psychedelic substances, with the goal of creating therapies that may offer therapeutic benefits without the hallucinogenic effects associated with some traditional psychedelics.
The company’s development programs have included BETR-001, a synthetic derivative of lysergic acid diethylamide (LSD) being studied for potential applications in depression and other neuropsychiatric disorders, and BETR-002, an ibogaine-derived compound being investigated for substance-use disorders and related conditions.
Further Reading
- Five stocks we like better than BetterLife Pharma
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
